Quantcast
Last updated on April 18, 2014 at 7:49 EDT

Latest Organofluorides Stories

2013-10-15 12:56:38

Scientists from the University of Sheffield have discovered ground breaking clues as to how the pioneering heart drug ticagrelor might reduce the risk of dying following a heart attack, in comparison to previous standard treatments. The new findings, published in Platelets, show that ticagrelor may reduce the risk of dying as a result of a lung infection after suffering a heart attack compared to patients treated with the drug clopidogrel. The analysis, which was led by researchers from...

2013-10-14 23:20:48

Reportbuyer.com just published a new market research report: Cardiovascular Disease: Recent Drug Advances and Impending Risks. London (PRWEB) October 14, 2013 There are nearly 300 medicines in clinical development to treat cardiovascular disease. This new research report examines in detail the key areas of the cardiovascular (CV) market, gathering inside opinion of cardiologists, to highlight the dynamic changes that are underway in this multibillion dollar marketplace. Successful...

2013-10-14 23:01:48

The Firm is investigating Januvia lawsuits on behalf of individuals who developed pancreatic cancer, pancreatitis or thyroid cancer, allegedly due to their use of Januvia. New York, New York (PRWEB) October 14, 2013 Januvia lawsuits ( http://www.januvialawsuithelp.com/), as well as product liability claims involving other incretin mimetic drugs, are preparing to move forward in a multidistrict litigation established in U.S. District Court, Southern District of California, Bernstein...

2013-10-11 23:02:07

The Firm is evaluating Lipitor lawsuits on behalf of individuals who were treated with the popular statin medication and developed Type 2 diabetes. New York, New York (PRWEB) October 11, 2013 As Lipitor lawsuit claims (http://www.thelipitorlawsuit.com/) continue to mount in courts throughout the U.S., Bernstein Liebhard LLP notes that all current and future Lipitor diabetes claims filed in the U.S. District Court for the Southern District of Illinois have been consolidated for the...

2013-10-08 20:22:34

First and only drug approved in U.S. to Treat Two Forms of Pulmonary Hypertension (WHO Group 1 and 4) WHIPPANY, N.J., Oct. 8, 2013 /PRNewswire/ -- Bayer HealthCare announced today that the United States Food and Drug Administration (FDA) has approved Adempas(®) (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO* Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO...

2013-10-07 08:25:26

SEATTLE, WA, Oct. 7, 2013 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today announced the presentation of final results from the first Phase 1 trial of ONT-380 at the American Association for Cancer Research Special Conference on Advances in Breast Cancer Research in San Diego. The results were presented by Virginia F. Borges, M.D., Associate Professor in the Division of Medical Oncology, University of Colorado School of Medicine. ONT-380 (also known as ARRY-380) is an orally...

2013-10-04 23:01:28

Bernstein Liebhard LLP is investigating Lipitor diabetes lawsuits on behalf of individuals who developed Type 2 diabetes, allegedly due to Lipitor New York, New York (PRWEB) October 04, 2013 As Lipitor lawsuit claims (http://www.thelipitorlawsuit.com/) involving allegations that the popular statin drug causes Type 2 diabetes continue to move forward in courts around the country, Bernstein Liebhard LLP notes that a newly-published study has found that statins like Lipitor may increase the...

2013-10-03 23:22:52

Reportbuyer.com just published a new market research report: PharmaPoint: Non-Small Cell Lung Cancer - US Drug Forecast and Market Analysis to 2022. London (PRWEB) October 03, 2013 PharmaPoint: Non-Small Cell Lung Cancer - US Drug Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of...

2013-10-02 23:02:27

The SAE MAC Refrigerant Blend Cooperative Research Program [MRB CRP] has continued its assessment of the operating, technical and safety performance of low GWP refrigerants. At meetings held in Urbana, Illinois on 24th-25th September the team reviewed the status of the development work into equipment for both production fill and service fill of the blended refrigerant AC6 (R445A). Warrendale, PA (PRWEB) October 02, 2013 The SAE International MAC Refrigerant Blend Cooperative Research...

2013-10-02 08:30:29

MIAMI, Fla. and NEW YORK, N.Y., Oct. 2, 2013 /PRNewswire/ -- Noven Pharmaceuticals, Inc., today announced that 11 presentations, featuring data analyses from its Phase 3 pivotal trials that supported the recent U.S. Food and Drug Administration approval of Brisdelle(TM) (paroxetine capsules, 7.5 mg/day) for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause, will be showcased at the 2013 Annual Meeting of The North American Menopause Society (NAMS) in...